LanZhou Foci Pharmaceutical Co.,Ltd.
Simbols: 002644.SZ
SHZ
7.78
CNYTirgus cena šodien
68.3675
P/E koeficients
-2.3694
PEG koeficients
3.97B
MRK Cap
- 0.01%
DIV ienesīgums
LanZhou Foci Pharmaceutical Co.,Ltd. (002644-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1413.19 | 406 | 398.5 | 374.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | -70.42 | -15.8 | 2 | -10.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 2046.86 | 441.8 | 526.5 | 390.8 | |||||||||||||||||
balance-sheet.row.inventory | 1526.12 | 369.7 | 350.4 | 258.8 | |||||||||||||||||
balance-sheet.row.other-current-assets | 74.04 | 21.3 | 15.7 | 10 | |||||||||||||||||
balance-sheet.row.total-current-assets | 5060.22 | 1238.9 | 1291.1 | 1034.6 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4211.94 | 1061.8 | 1066.8 | 1091.6 | |||||||||||||||||
balance-sheet.row.goodwill | 26.96 | 9 | 4.5 | 4.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 320.66 | 79.6 | 76.8 | 72 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 347.63 | 88.6 | 81.3 | 76.4 | |||||||||||||||||
balance-sheet.row.long-term-investments | 335.99 | 79.9 | 66.7 | 82.1 | |||||||||||||||||
balance-sheet.row.tax-assets | 205.41 | 53.6 | 52.4 | 51.1 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 54.24 | 5.3 | 28.4 | 16.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 5155.21 | 1289.2 | 1295.5 | 1317.5 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 10215.43 | 2528.1 | 2586.6 | 2352.1 | |||||||||||||||||
balance-sheet.row.account-payables | 1338.65 | 310.4 | 311 | 214.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 98.74 | 24.7 | 13.8 | 14.7 | |||||||||||||||||
balance-sheet.row.tax-payables | 130.95 | 35.1 | 69.4 | 47.6 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 14.55 | 1.3 | 0.5 | 0.8 | |||||||||||||||||
Deferred Revenue Non Current | 1056.95 | 261 | 278.2 | 295 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 10.03 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 19.4 | 5.8 | 110.9 | 4.5 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1174.53 | 292 | 322.1 | 349.8 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 3.23 | 1.3 | 0.5 | 0.8 | |||||||||||||||||
balance-sheet.row.total-liab | 3126.08 | 759.7 | 852.6 | 724.6 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 2042.63 | 510.7 | 510.7 | 510.7 | |||||||||||||||||
balance-sheet.row.retained-earnings | 3119.21 | 776.2 | 746.9 | 654.5 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1237.35 | 158.4 | 152 | 143.6 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 605.87 | 300.1 | 305.8 | 305.8 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 7005.06 | 1745.4 | 1715.4 | 1614.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 10215.43 | 2528.1 | 2586.6 | 2352.1 | |||||||||||||||||
balance-sheet.row.minority-interest | 84.28 | 23.1 | 18.6 | 12.9 | |||||||||||||||||
balance-sheet.row.total-equity | 7089.35 | 1768.4 | 1734 | 1627.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 10215.43 | - | - | - | |||||||||||||||||
Total Investments | 265.57 | 64.1 | 68.7 | 71.7 | |||||||||||||||||
balance-sheet.row.total-debt | 113.29 | 26 | 14.4 | 15.5 | |||||||||||||||||
balance-sheet.row.net-debt | -1299.9 | -380 | -382.1 | -359.4 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 58.12 | 68.1 | 105.9 | 93.5 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 3.63 | 52.5 | 49.5 | 48.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0.2 | 1 | 0.2 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -0.2 | -1 | -0.2 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 66.85 | -82.3 | -112.2 | -117 | |||||||||||||||||
cash-flows.row.account-receivables | 59.5 | 59.5 | -210.1 | -66.8 | |||||||||||||||||
cash-flows.row.inventory | -7.3 | -7.3 | -91.7 | -0.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -134.7 | 188.6 | -49.5 | |||||||||||||||||
cash-flows.row.other-working-capital | 14.64 | 0.2 | 1 | 0.2 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -71.03 | 27.4 | 29.1 | -13.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 57.56 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -8.98 | -22.5 | -41.5 | -32.8 | |||||||||||||||||
cash-flows.row.acquisitions-net | -15.45 | -15.5 | 3.9 | 74.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 8.95 | -6 | -2.1 | -3.9 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 7.98 | 8 | -3.9 | 38.1 | |||||||||||||||||
cash-flows.row.other-investing-activites | -15.17 | 1.8 | 0.8 | -32.8 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -22.66 | -34.2 | -42.8 | 42.6 | |||||||||||||||||
cash-flows.row.debt-repayment | -22.59 | -21.5 | -14.2 | -35.3 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | -1.65 | -27.9 | -5.1 | -61.4 | |||||||||||||||||
cash-flows.row.other-financing-activites | -11.1 | -1.3 | 3.9 | 3.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -50.87 | -25 | -15.5 | -93.4 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 25.84 | 0.7 | 0.7 | -0.2 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 9.86 | 7.2 | 14.8 | -39.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1376.43 | 396.3 | 387.7 | 372.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1366.56 | 389.1 | 372.9 | 412 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 57.56 | 65.7 | 72.4 | 11.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | -8.98 | -22.5 | -41.5 | -32.8 | |||||||||||||||||
cash-flows.row.free-cash-flow | 48.58 | 43.2 | 30.9 | -21 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1130.07 | 1163.1 | 1019.2 | 817.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 765.41 | 801.8 | 733 | 594.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 364.66 | 361.3 | 286.2 | 223.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 31.51 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 17.15 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 154.39 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -2.01 | -1.6 | -9.7 | 24.4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 262.09 | 262 | 129.4 | 134.6 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 1027.5 | 1063.8 | 862.3 | 729 | |||||||||||||||||
income-statement-row.row.interest-income | 2.93 | 5.4 | 7.5 | 10.2 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.2 | 0.7 | 0.9 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 154.39 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -2.01 | -1.6 | -12.4 | -1.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -2.01 | -1.6 | -9.7 | 24.4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -2.01 | -1.6 | -12.4 | -1.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.2 | 0.7 | 0.9 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 40.06 | 52.5 | 62.2 | 32.2 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 112.68 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 72.62 | 83.3 | 139.4 | 112.4 | |||||||||||||||||
income-statement-row.row.income-before-tax | 70.6 | 81.6 | 127 | 110.8 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 11.28 | 13.5 | 21.1 | 17.3 | |||||||||||||||||
income-statement-row.row.net-income | 58.12 | 67.2 | 108.7 | 93.3 |
Biežāk uzdotie jautājumi
Kas ir LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) kopējie aktīvi?
LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) kopējie aktīvi ir 2528102214.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 576952643.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.323.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.095.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.051.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.064.
Kāda ir LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 67189706.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 26031519.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 261964435.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 365338610.000.